GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Sale Of Property, Plant, Equipment

ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) Sale Of Property, Plant, Equipment : €-0.04 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Sale Of Property, Plant, Equipment?

ImmuneOnco Biopharmaceuticals (Shanghai)'s sale of property, plant, equipment for the six months ended in Jun. 2024 was €0.00 Mil. It means ImmuneOnco Biopharmaceuticals (Shanghai) gained €0.00 Mil from selling property, plant, and equipment. ImmuneOnco Biopharmaceuticals (Shanghai)'s sale of property, plant, equipment for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.04 Mil.

Compared with last quarter (€-0.04 Mil in Dec. 2023 ), ImmuneOnco Biopharmaceuticals (Shanghai) gained more money from selling property, plant, and equipment in Jun. 2024 (€0.00 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai) Sale Of Property, Plant, Equipment Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Sale Of Property, Plant, Equipment Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Sale Of Property, Plant, Equipment
0.08 0.89 - -

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial - 0.04 -0.04 - -

ImmuneOnco Biopharmaceuticals (Shanghai) Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
HKSE:06996 HKSE:06978 HKSE:02181 HKSE:01521 HKSE:02509 HKSE:02487 HKSE:02137 HKSE:02566 HKSE:02563 HKSE:01167 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
01541:Hong Kong
Address
1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
Website
http://cn.immuneonco.com
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines